RETENTION RATES OF ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB AS BIOTHERAPIES FOR RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS PATIENTS IN DAILY PRACTICE IN AUVERGNE (FRANCE)

被引：0
|
作者：
Soubrier, M. [1 ]
Fan, A. [1 ]
Couderc, M. [1 ]
Malochet-Guinamand, S. [1 ]
Mathieu, S. [1 ]
Giraud, C. [1 ]
Tournadre, A. [1 ]
Dubost, J. -J. [1 ]
Pereira, B. [2 ]
机构：
[1] CHU Clermont Ferrand, Dept Rheumatol, Clermont Ferrand, France
[2] CHU Clermont Ferrand, Biostat Unit, Clermont Ferrand, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1333
引用
收藏
页码：1756 / 1756
页数：1
相关论文
共 50 条
  • [21] Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients
    Brocq, O
    Albert, C
    Roux, C
    Gerard, D
    Breuil, V
    Ziegler, LE
    JOINT BONE SPINE, 2004, 71 (06) : 601 - 603
  • [22] Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
    Neovius, M.
    Arkema, E. V.
    Olsson, H.
    Eriksson, J. K.
    Kristensen, L. E.
    Simard, J. F.
    Askling, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 354 - 360
  • [23] Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis
    Titos Arcos, Jose Carlos
    Hallal, Hacibe
    Robles, Mercedes
    Andrade, Raul J.
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2012, 104 (05) : 282 - 284
  • [24] Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation
    Rodgers, M.
    Epstein, D.
    Bojke, L.
    Yang, H.
    Craig, D.
    Fonseca, T.
    Myers, L.
    Bruce, I.
    Chalmers, R.
    Bujkiewicz, S.
    Lai, M.
    Cooper, N.
    Abrams, K.
    Spiegelhalter, D.
    Sutton, A.
    Sculpher, M.
    Woolacott, N.
    HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (10) : 1 - +
  • [25] Safety of infliximab in daily practice in patients with rheumatoid arthritis.
    Neven, N
    Vis, M
    Voskuyl, AE
    Wolbink, GJ
    Nurmohamed, MT
    Dijkmans, BAC
    Lems, WF
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S331 - S331
  • [26] Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice
    Wendling, D
    Materne, GE
    Michel, F
    Lohse, A
    Lehuede, G
    Toussirot, E
    Massol, J
    Woronoff-Lemsi, MC
    JOINT BONE SPINE, 2005, 72 (04) : 309 - 312
  • [27] DOWN-TITRATION AND DISCONTINUATION OF INFLIXIMAB, ADALIMUMAB AND ETANERCEPT IN ESTABLISHED RHEUMATOID ARTHRITIS
    Lojo, L.
    Bonilla, G.
    Peiteado, D.
    Villalba, A.
    Plasencia, C.
    Nuno, L.
    Balsa, A.
    Martin-Mola, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 237 - 237
  • [28] The 6-month change in disease activity and disability after treatment with adalimumab compared to etanercept and infliximab in patients with rheumatoid arthritis in daily clinical practice
    Kievit, W.
    Fransen, J.
    Brus, H. C.
    De Gendt, C. M.
    Jansen, T. L.
    Janson, M.
    Kupper, H. H.
    Moolenburgh, J. D.
    Van Oijen, P. L. M.
    D'Amelio, R.
    Ronday, K. H.
    De Rooij, D. J. R. A.
    Adang, E. E.
    Van Riel, P. L. C. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 325 - 325
  • [29] Correlations of fatigue in Danish patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis
    Esbensen, Bente Appel
    Stallknecht, Sandra Elkjaer
    Madsen, Maria Elmegaard
    Hagelund, Lise
    Pilgaard, Trine
    PLOS ONE, 2020, 15 (08):
  • [30] THE IMPACT OF CHANGES IN ADALIMUMAB, ETANERCEPT, AND INFLIXIMAB DOSES ON THE COSTS OF TREATING RHEUMATOID ARTHRITIS
    Lawson, R. W.
    Heatley, R. M.
    Johnson, K., I
    Khandker, R. K.
    Singh, A.
    VALUE IN HEALTH, 2010, 13 (07) : A308 - A308
12345